April 24, 2019
Rexgenero Presents Update on Phase III Clinical Trials with REX-001, a Cell-based Therapy for Critical Limb Ischaemia
Rexgenero presented an update on its two Phase III SALAMANDER trials beingconducted across Europe for its lead development programme REX-001 totreat CLI in patients with diabetes.